China approves Alzheimer's drug

The State Food and Drug Administration of China (CFDA) has conditionally approved the application for the listing of the Ganlut sodium capsule (trade name “Nine Phase One”) for mild to moderate Alzheimer's disease and improved cognitive function. The drug is a low-molecular acidic oligosaccharide compound prepared by extracting marine brown algae as a raw material. It is an innovative drug independently researched and developed by China and possessing independent intellectual property rights. It has won major national special new drug creation technology and special support. The pathogenesis of Alzheimer's disease is very complicated, the duration of the disease is long, and the cure is difficult. The listing of the drug will provide patients with new drug options.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001380 seconds